Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure.
PD-1
PD-L1
acquired resistance
immune checkpoint inhibitors
immunotherapy
lung cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
20 Dec 2020
20 Dec 2020
Historique:
received:
10
11
2020
revised:
14
12
2020
accepted:
15
12
2020
entrez:
9
1
2021
pubmed:
10
1
2021
medline:
10
1
2021
Statut:
epublish
Résumé
Immunotherapy is now the preferred treatment for most lung cancer patients. It is used to treat unresectable stage III non-small-cell lung cancer and is the first-line therapy for non-oncogene-driven advanced/metastatic non-small-cell lung cancer patients (either alone or in combination with chemotherapy). Unfortunately, most patients that respond initially to immunotherapy develop resistance over time, thus limiting the durability of immunotherapy. A better understanding of the mechanisms of acquired resistance is urgently needed to expand the benefit of immunotherapy in lung cancer patients. This review aims to summarize the mechanisms and clinical outcomes of acquired resistance of anti-PD-1/PD-L1 therapies in non-small-cell lung cancer patients.
Identifiants
pubmed: 33419311
pii: cancers12123851
doi: 10.3390/cancers12123851
pmc: PMC7767234
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
J Thorac Oncol. 2018 Jun;13(6):831-839
pubmed: 29578107
Curr Opin Immunol. 2015 Apr;33:120-5
pubmed: 25728992
Cancer Immunol Res. 2019 Jan;7(1):77-85
pubmed: 30425105
J Transl Med. 2018 Aug 6;16(1):219
pubmed: 30081936
Sci Transl Med. 2013 Aug 28;5(200):200ra116
pubmed: 23986400
Science. 2016 Dec 2;354(6316):1160-1165
pubmed: 27789795
Curr Opin Immunol. 2015 Apr;33:23-35
pubmed: 25621841
Cell. 2015 Sep 10;162(6):1229-41
pubmed: 26321679
J Biomed Biotechnol. 2011;2011:918471
pubmed: 22190859
Cell. 2017 Nov 30;171(6):1259-1271.e11
pubmed: 29107330
Cancer Discov. 2017 Dec;7(12):1420-1435
pubmed: 29025772
Int Immunol. 2007 Jul;19(7):813-24
pubmed: 17606980
Semin Cancer Biol. 2015 Dec;35 Suppl:S185-S198
pubmed: 25818339
Cancer Discov. 2018 Jul;8(7):822-835
pubmed: 29773717
Pharmacol Ther. 2019 Apr;196:105-116
pubmed: 30521884
J Immunother Cancer. 2019 Jul 24;7(1):196
pubmed: 31340861
Cancer Res. 2004 Feb 1;64(3):1140-5
pubmed: 14871849
Cell. 2017 Nov 30;171(6):1272-1283.e15
pubmed: 29107334
Br J Cancer. 2015 Apr 28;112(9):1501-9
pubmed: 25867264
Front Immunol. 2014 Jul 10;5:304
pubmed: 25071765
Am Soc Clin Oncol Educ Book. 2019 Jan;39:165-174
pubmed: 31099649
Science. 2019 May 10;364(6440):558-566
pubmed: 31000591
Ann Oncol. 2018 Jun 1;29(6):1437-1444
pubmed: 29617710
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
pubmed: 12218188
Cancer Immunol Res. 2015 May;3(5):506-17
pubmed: 25672397
J Clin Oncol. 2019 Aug 1;37(22):1927-1934
pubmed: 31206316
Science. 2013 Mar 29;339(6127):1546-58
pubmed: 23539594
Immunity. 2018 Mar 20;48(3):434-452
pubmed: 29562194
Cancer. 2020 Jan 1;126(1):86-97
pubmed: 31584722
Cancer Cell. 2019 Feb 11;35(2):238-255.e6
pubmed: 30753825
Oncoimmunology. 2013 Sep 1;2(9):e26246
pubmed: 24319640
Cancer Immunol Res. 2016 Mar;4(3):194-203
pubmed: 26787823
J Clin Oncol. 2018 Oct 1;36(28):2872-2878
pubmed: 30125216
Oncotarget. 2017 Dec 15;9(4):4375-4384
pubmed: 29435109
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
Clin Cancer Res. 2018 Apr 15;24(8):1872-1880
pubmed: 29330207
Science. 2017 Mar 31;355(6332):1428-1433
pubmed: 28280247
Cancer Immunol Immunother. 2018 Aug;67(8):1271-1284
pubmed: 29923026
Front Immunol. 2020 May 15;11:783
pubmed: 32508809
Proc Natl Acad Sci U S A. 2020 Mar 3;117(9):4447-4449
pubmed: 32102915
Nature. 2017 Jul 27;547(7664):413-418
pubmed: 28723893
Cancer Discov. 2017 Feb;7(2):188-201
pubmed: 27903500
Oncoimmunology. 2019 Sep 23;8(12):e1665973
pubmed: 31741763
Cancer Discov. 2017 Mar;7(3):264-276
pubmed: 28031159
J Exp Med. 2010 Sep 27;207(10):2175-86
pubmed: 20819923
Br J Cancer. 2018 Jan;118(1):9-16
pubmed: 29319049
Nature. 2017 May 25;545(7655):452-456
pubmed: 28514453
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
Science. 2015 Nov 27;350(6264):1084-9
pubmed: 26541606
Cancer Lett. 2019 Aug 10;457:168-179
pubmed: 31078738
JCI Insight. 2018 Dec 20;3(24):
pubmed: 30568030
Nat Med. 2002 Aug;8(8):793-800
pubmed: 12091876
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
Int J Mol Sci. 2018 Dec 02;19(12):
pubmed: 30513816
JAMA Oncol. 2019 Dec 1;5(12):1774-1778
pubmed: 31513236
Ann Thorac Surg. 2019 Feb;107(2):393-400
pubmed: 30343006
Nat Med. 2018 Dec;24(12):1852-1858
pubmed: 30478423
Sci Transl Med. 2017 May 10;9(389):
pubmed: 28490665
Int J Oncol. 2009 Oct;35(4):741-9
pubmed: 19724910
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
Am Soc Clin Oncol Educ Book. 2019 Jan;39:147-164
pubmed: 31099674
Nat Commun. 2016 Feb 17;7:10501
pubmed: 26883990
Clin Cancer Res. 2018 Nov 1;24(21):5368-5380
pubmed: 30042205
Sci Transl Med. 2018 Dec 5;10(470):
pubmed: 30518613
Cancer Res. 2005 Feb 1;65(3):1089-96
pubmed: 15705911
Neoplasia. 2017 Oct;19(10):848-855
pubmed: 28923537
Nat Rev Immunol. 2018 Mar;18(3):153-167
pubmed: 28990585
Cancer Res. 2018 Feb 15;78(4):1003-1016
pubmed: 29229601
Ann Oncol. 2019 Oct 1;30(10):1572-1579
pubmed: 31268133
Science. 2013 Nov 22;342(6161):967-70
pubmed: 24264989
Nat Commun. 2020 Jan 30;11(1):602
pubmed: 32001684
Nat Med. 2018 Oct;24(10):1545-1549
pubmed: 30127394